Crinetics to highlight neuroendocrine tumor research progress at NANETS 2025

Crinetics (CRNX) Pharmaceuticals announced three abstracts from its clinical development programs will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Meeting, taking place October 23-25, 2025, in Austin, Texas. “At the 2025 NANETS annual meeting, we are excited to showcase the continued progress of multiple development programs focused on the treatment of neuroendocrine tumors,” said Dana Pizzuti, M.D., Chief Medical and Development Officer at Crinetics. “For the first time, we will present progression-free survival data from our Phase 2 study of paltusotine for the treatment of carcinoid syndrome associated with NETs. Details of recently-initiated clinical trials for both paltusotine and our nonpeptide drug candidate CRN09682 program will also be presented, demonstrating our deep commitment and continued momentum in the NETs space.” A preliminary analysis of Phase 2 data from the open-label trial of paltusotine in the treatment of patients with carcinoid syndrome due to NETs will be featured in a poster presentation, showing an overall investigator-assessed progression free survival rate of 74% following one year of treatment. Paltusotine is approved as PALSONIFY in the U.S. as a once-daily oral for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is currently being investigated for new indications, including for the treatment of carcinoid syndrome; it is not currently approved in the U.S. or any other countries for the treatment of carcinoid syndrome. Two additional poster presentations will feature study details from the randomized, Phase 3 trial of paltusotine in carcinoid syndrome due to NETs and the first-in-human study of NDC candidate CRN09682 in patients with somatostatin receptor 2-expressing tumors.